Next-Generation Approaches for the Treatment of Food Allergy
- 104 Downloads
Purpose of Review
IgE-mediated food allergies are an increasing health concern, and current management includes food avoidance and use of emergency medications. Effective treatment of food allergy is highly desirable. Next generation approaches for the treatment of food allergy aim to improve both safety and efficacy, potentially including long-term tolerance.
Oral immunotherapy (OIT) and epicutaneous immunotherapy (EPIT) will likely be integrated into clinical practice as part of food allergy management in the near future. Newer approaches, such as sublingual immunotherapy (SLIT), modified proteins, lysosomal-associated membrane protein DNA (LAMP DNA) vaccines, and the use of immunomodulatory agents, are early in development and depending on results, could also become important treatment options.
This is a review of novel approaches to the treatment of food allergy that are currently under investigation, including the use of SLIT, modified proteins, probiotics, Chinese herbal supplements, biologic therapies, and DNA vaccines, as well as a summary of the current status of OIT and EPIT.
KeywordsFood allergy Treatment Immunotherapy Biologic therapy Modified proteins DNA vaccine
Compliance with Ethical Standards
Conflict of Interest
Dr. Dantzer reports grants from NIH, grants from Aimmune, and personal fees from Maryland Chapter of the American Academy of Pediatrics, outside the submitted work; Dr. Wood reports grants from NIH, from Aimmune, from Astellas, from DBV, from Sanofi, from regeneron, and other from Up To Date, outside the submitted work.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 10.Michelsen-Huisman AD, van Os-Medendorp H, Blom WM, Versluis A, Castenmiller JJM, Noteborn HPJM, et al. Accidental allergic reactions in food allergy: causes related to products and patient’s management. Allergy. 2018; 73(12):2377-2381.Google Scholar
- 26.• Vickery BP, Berglund JP, Burk CM, Fine JP, Kim EH, Kim JI, et al. Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective. J Allergy Clin Immunol. 2017;139(1):173–181.e8 Study showing the safety and efficacy of peanut OIT in young children. CrossRefGoogle Scholar
- 27.•• Bird JA, Spergel JM, Jones SM, Rachid R, Assa’ad AH, Wang J, et al. Efficacy and safety of AR101 in oral immunotherapy for peanut allergy: results of ARC001, a randomized, double-blind, placebo-controlled phase 2 clinical trial. J Allergy Clin Immunol Pract. 2018;6(2):476–485.e3 Phase 2 results from AR101 product that will be submitted to the FDA for new drug licensing. CrossRefGoogle Scholar
- 32.Begin P, Winterroth LC, Dominguez T, Wilson SP, Bacal L, Mehrotra A, et al. Safety and feasibility of oral immunotherapy to multiple allergens for food allergy. Allergy Asthma Clin Immunol. 2014;10(1):1-1492-10-1.Google Scholar
- 35.Goldberg MR, Nachshon L, Appel MY, Elizur A, Levy MB, Eisenberg E, et al. Efficacy of baked milk oral immunotherapy in bakedmilk-reactive allergic patients. J Allergy Clin Immunol. 2015; 136(6):1601-1606.Google Scholar
- 42.Xolair(R) [package insert]. Genentech, Inc., South San Francisco, CA, 2007. 2017; Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/103976s5102lbl.pdf. Accessed September 12, 2017.
- 44.• Wood RA, Kim JS, Lindblad R, Nadeau K, Henning AK, Dawson P, et al. A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow’s milk allergy. J Allergy Clin Immunol. 2016;137(4):1103–10.e1–11 Study showing that omalizumab plus OIT improved safety, but not efficacy. CrossRefGoogle Scholar
- 47.Lin C, Lee IT, Sampath V, Dinakar C,DeKruyff RH, Schneider LC, et al. Combining anti-IgEwith oral immunotherapy. Pediatr Allergy Immunol. 2017; 28(7): 619-627.Google Scholar
- 48.•• Jones SM, Sicherer SH, Burks AW, Leung DY, Lindblad RW, Dawson P, et al. Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adults. J Allergy Clin Immunol. 2017;139(4):1242–1252.e9 Phase II results on the safety and efficacy of Viaskin peanut patch therapy, which was submitted to the FDA for licensing in October 2018. CrossRefGoogle Scholar
- 52.Sampson HA, Shreffler WG, Yang WH, Sussman GL, Brown-Whitehorn TF, Nadeau KC, et al. Effect of varying doses of epicutaneous immunotherapy vs placebo on reaction to peanut protein exposure among patients with peanut sensitivity: a randomized clinical trial. JAMA. 2017;318(18):1798–809.CrossRefGoogle Scholar
- 66.Marco Londei M, Brian Kenney B, Gerrit Los P, Margaret MP. A phase 1 study of ANB020, an anti-IL-33 monoclonal antibody, in healthy volunteers. J Am Acad Dermatol. 2017; 2018/11;76(6):AB20.Google Scholar
- 68.Bindslev-Jensen C, de Kam P, van Twuijver E, Boot DB, El Galta R, Mose AP, et al. SCIT-treatment with a chemically modified, aluminum hydroxide adsorbed peanut extract (HAL-MPE1) was generally safe and well tolerated and showed immunological changes in peanut allergic patients. J Allergy Clin Immunol. 2017; 2018/10;139(2):AB191.CrossRefGoogle Scholar